Online citations, reference lists, and bibliographies.
← Back to Search

Adjustment Of Magnesium Sulfate Infusion Rate In Patients With Preterm Labor.

M. Simchen, M. Dulitzky, S. Mashiach, S. Friedman, E. Schiff
Published 1998 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE Our purpose was to investigate factors that might influence serum magnesium levels during intravenous magnesium sulfate tocolytic therapy. STUDY DESIGN Thirty-three women receiving magnesium sulfate for preterm labor participated in this prospective, observational study. Gestational ages were 24 to 34 weeks. Four groups of women were identified according to the maintenance magnesium infusion rate required for arresting preterm labor after 5 g of therapy induction: 1.5, 2, 2.5, and 3 g/h. Serum magnesium samples were drawn after a predefined period of at least 18 hours of arrested preterm labor, at a minimum of every 6 hours. Variables examined included serum albumin; serum protein; serum ionized calcium; serum creatinine; creatinine clearance; 24-hour urine output; maternal height, weight, body surface area; and body mass index. RESULTS By use of a multivariate stepwise regression model we identified four variables that independently and significantly contributed to the model: magnesium infusion rate (P < .001); total serum protein level (P < .001); serum creatinine level (P = .009); and maternal weight squared (P = .026). Seventy-two percent of the variance was accounted for by use of these parameters. A predictive linear model, developed to relate these factors, produced the following formula: Suggested magnesium infusion rate = 0.89 x Serum magnesium concentration (mg/dL) - 3.16 x Serum creatinine (mg/dL) - 0.66 x Serum total proteins (g/dL) + 0.0001 x (maternal weight)2 (kg) + 2.30. CONCLUSIONS Serum creatinine, serum protein, and maternal weight can be used to adjust the dose of magnesium sulfate in patients with premature labor to achieve therapeutic serum levels of magnesium more rapidly and safely.
This paper references
Urinary Magnesium, Calcium, and Phosphate Excretion During Magnesium Sulfate Infusion
D. P. Cruikshank (1981)
10.1016/S0146-0005(95)80050-6
Pharmacologic management of preterm labor.
M. Monga (1995)
10.1097/00006254-199710000-00023
Evidence for magnesium sulfate as a tocolytic agent.
G. Macones (1997)
10.1136/adc.64.10.1524-b
Maternal Fetal Medicine. Principles and Practice
M. A. Maresh (1984)
10.1097/00132586-197006000-00035
Aggressive toxemia management (preeclampsia and eclampsia).
S. F. Rogers (1969)
10.1055/S-2007-994388
Intravenous magnesium sulfate for premature labor: comparison between twin and singleton gestations.
K. Hales (1995)
10.1016/0002-9378(90)91090-Y
Adjusting the loading dose of magnesium sulfate for tocolysis.
J. Wright (1990)
10.1016/0002-9378(83)91111-0
Magnesium sulfate as a tocolytic agent.
J. Elliott (1983)
10.1016/S0002-9378(88)80035-8
Efficacy and side effects of magnesium sulfate and ritodrine as tocolytic agents.
I. Wilkins (1988)
10.1016/0002-9378(77)90808-0
A comparison of magnesium sulfate and alcohol for the prevention of premature labor.
C. Steer (1977)
10.1097/00003081-198809000-00010
Pharmacologic treatment of preterm labor.
S. Caritis (1988)
10.1016/0002-9378(87)90066-4
Magnesium sulfate and ritodrine hydrochloride: a randomized comparison.
D. Hollander (1987)
10.1016/0002-9378(59)90635-0
The effects of magnesium therapy on the duration of labor.
D. Hall (1959)
10.1016/0020-7292(84)90024-9
The use of ritodrine and magnesium sulfate in the arrest of premature labor
Nubar G. Tchilingurian (1984)
Magnesium sulfate in toxemia of pregnancy. New dosage schedule based on body weight.
Flowers Ce (1962)
10.1093/MILMED/151.1.386
Goodman and Gilman's the Pharmacological Basis of Therapeutics
W. Stigelman (1986)
10.1016/0002-9378(85)90689-1
A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor.
M. Beall (1985)
Serum magnesium levels during magnesium sulfate tocolysis in high-order multiple gestations.
Elliott Jp (1995)



This paper is referenced by
10.15296/IJWHR.2014.23
Fetal & Neonatal Outcomes of the Magnesium Sulfate and Nefidipine in Suppression of Preterm Labor
Fartash Fereshteh (2014)
10.1016/j.ijgo.2004.01.003
Low dose treatment protocol in magnesium sulfate tocolysis
C. Soguk (2004)
10.1016/S0020-7292(99)00163-0
Intrapartum fetal distress and magnesium sulfate
P. Vigil-De Gracia (2000)
10.17160/josha.7.1.628
EVALUATION OF THE DETERMINANTS OF MAGNESEMIA IN PATIENTS WITH PREECLAMPSIA WITH SEVERE FEATURES TREATED ACCORDING TO 2013 TASK FORCE FIGO PROTOCOL
A. Díaz (2020)
10.1067/MOB.2000.107334
A prospective, randomized, controlled trial of high and low maintenance doses of magnesium sulfate for acute tocolysis.
D. Terrone (2000)
THE ASSOCIATION BETWEEN MATERNAL SERUM MAGNESIUM LEVEL AND PREGNANCY OUTCOMES
E. Jenabi (2017)
10.1111/jog.12690
Factors affecting maternal serum magnesium levels during long‐term magnesium sulfate tocolysis in singleton and twin pregnancy
Hiroshi Nakazawa (2015)
10.1067/MOB.2002.123897
Magnesium sulfate inhibits the oxytocin-induced production of inositol 1,4,5-trisphosphate in cultured human myometrial cells.
W. Hurd (2002)
10.1111/j.1447-0756.2007.00508.x
Ionized and total magnesium concentration in patients with severe preeclampsia‐eclampsia undergoing magnesium sulfate therapy
B. S. Aali (2007)
10.1186/1471-2393-14-222
The BRAzil MAGnesium (BRAMAG) trial: a randomized clinical trial of oral magnesium supplementation in pregnancy for the prevention of preterm birth and perinatal and maternal morbidity
J. Alves (2014)
10.1067/MOB.2002.122421
Pharmacokinetics of ionized versus total magnesium in subjects with preterm labor and preeclampsia.
E. Taber (2002)
Semantic Scholar Logo Some data provided by SemanticScholar